ALK inhibitors are highly effective in patients with ALK-rearranged NSCLC.17,18,21,22 Thus, we also examined the effects of ALK inhibitors on RDAA lung cancer cells in vitro and in vivo. This evidence concerns the gene ALK and non-small cell lung carcinoma.